bims-evecad Biomed News
on Extracellular vesicles and cardiovascular disease
Issue of 2026–02–15
ten papers selected by
Cliff Dominy



  1. Ewha Med J. 2026 Jan;49(1): e3
      Cardiovascular disease, particularly ischemic heart disease, remains a leading cause of death worldwide. Although advances in pharmacological and device-based therapies have improved clinical outcomes, effective strategies for myocardial repair and regeneration remain limited. T-cadherin, a glycosylphosphatidylinositol-anchored atypical cadherin, has recently been identified as a functional receptor for both low-density lipoprotein cholesterol and adiponectin, a cardioprotective adipokine. Notably, the interaction between T-cadherin and adiponectin has emerged as a key regulator of exosome biogenesis and paracrine signaling within cardiovascular tissues. Exosomes are nanosized extracellular vesicles that carry protective molecular cargo, including microRNAs and proteins, and contribute to anti-inflammatory, antifibrotic, and angiogenic effects in the ischemic myocardium. However, their clinical translation is challenged by factors such as variability in yield, heterogeneity of exosome populations, and inefficient tissue targeting. Enhancing endogenous exosome production through the T-cadherin-adiponectin pathway may therefore offer a novel cell-free therapeutic strategy. This review explores the biological roles of T-cadherin and adiponectin in cardiovascular diseases, their regulatory influence on exosome formation, and the future potential of leveraging this axis for myocardial repair and regeneration.
    Keywords:  Adiponectin; Cardiovascular diseases; Extracellular vesicles; Regenerative medicine; T-cadherin
    DOI:  https://doi.org/10.12771/emj.2025.01067
  2. Nephrol Dial Transplant. 2026 Feb 09. pii: gfag022. [Epub ahead of print]
      Chronic Kidney Disease (CKD) is a major public health concern, closely linked to an increased risk of cardiovascular disease (CVD), which remains the leading cause of morbidity and mortality in this population. While traditional risk factors such as hypertension and diabetes are prevalent in CKD, disease-specific mechanisms-including chronic inflammation, oxidative stress, mineral disturbances, and the accumulation of uremic toxins-further amplify cardiovascular vulnerability. In CKD, both the abundance and molecular cargo of circulating extracellular vesicles (EVs) are altered, reflecting the underlying metabolic and inflammatory milieu. These EVs propagate endothelial dysfunction, vascular calcification, inflammation, thrombosis, and cardiac remodelling by transferring bioactive molecules such as proteins and microRNAs to target cells. Emerging evidence suggests that EVs not only serve as biomarkers for early detection and risk stratification of CVD in CKD but may also represent novel therapeutic targets. Preclinical studies demonstrate the potential of stem cell-derived and engineered EVs to promote cardiac repair and modulate pathological signalling. However, translation into clinical practice requires rigorous standardization, safety validation, and well-designed human trials. This review synthesizes current knowledge on the mechanisms by which EVs bridge renal dysfunction and cardiovascular pathology, discusses their utility as biomarkers, and outlines a research agenda for harnessing their therapeutic potential in CKD-associated CVD.
    Keywords:  cardiovascular disease; chronic kidney disease; extracellular vesicles
    DOI:  https://doi.org/10.1093/ndt/gfag022
  3. Ann Med Surg (Lond). 2026 Feb;88(2): 2124-2125
      Extracellular vesicles (EVs), particularly exosomes, have emerged as key mediators of intercellular communication by transporting microRNAs (miRNAs). Recent studies indicate that EV-associated miRNAs regulate gene expression across diverse physiological and pathological processes, including cancer metastasis, neuroinflammation, kidney injury, and cardiovascular disease. Understanding the selective packaging, trafficking, and functional consequences of EV-miRNA transfer may enable the development of biomarkers and targeted therapies based on vesicle-mediated signaling.
    Keywords:  biomarkers; exosomes; extracellular vesicles; intercellular communication; microRNA; precision medicine
    DOI:  https://doi.org/10.1097/MS9.0000000000004579
  4. Int Immunopharmacol. 2026 Feb 09. pii: S1567-5769(26)00115-3. [Epub ahead of print]174 116272
       BACKGROUND: Acute myocardial infarction (AMI) is a leading global cause of death, with extracellular vesicles (EVs) emerging as potential therapeutic mediators. However, the mechanisms by which circulating EVs from different sources influence myocardial injury remain unclear.
    METHOD: Circulating EVs from AMI patients (AMI-EVs) and healthy controls (N-EVs) were isolated. In vitro assays (CCK8, EdU, flow cytometry, wound healing, angiogenesis) evaluated their effects on cardiomyocyte/endothelial cell proliferation, apoptosis, migration, and tube formation. Immune cell infiltration and immunoglobulin levels in myocardial injury patients were analyzed. Microarray and qPCR identified differentially expressed miRNAs in EVs. CYP1B1, predicted as a target of miR-16-5p via bioinformatics, was validated using dual-luciferase reporter and RNA co-immunoprecipitation. An ischemia-reperfusion (I/R) mouse model assessed EV effects on myocardial injury and PANoptosis.
    RESULT: N-EVs alleviated I/R-induced myocardial injury in vivo and protected cardiomyocytes/endothelial cells from H2O2-induced damage in vitro. Patients with myocardial injury exhibited IgG deposits, immune cell infiltration, and elevated IgG1/IgG3 levels. N-EVs promoted angiogenesis and cardiomyocyte proliferation while suppressing PANoptosis (combined apoptosis, necroptosis, pyroptosis). Mechanistically, miR-16-5p was enriched in N-EVs and directly targeted CYP1B1, inhibiting its expression and downstream PANoptosis pathways.
    CONCLUSION: N-EVs mitigate myocardial injury by delivering miR-16-5p to suppress CYP1B1-mediated PANoptosis, highlighting their role in intercellular communication and therapeutic potential for AMI. This study provides insights into EV-based strategies for cardiac repair and fibrosis prevention.
    Keywords:  EVs; IgG; Myocardial injury; PANoptosis; miR-16-5p
    DOI:  https://doi.org/10.1016/j.intimp.2026.116272
  5. Rev Cardiovasc Med. 2026 Jan;27(1): 46117
      Heart failure (HF) represents a class of cardiovascular diseases that poses a serious threat to global health. Although current pharmacological and device-based therapies have exhibited some progress, significant challenges remain, including suboptimal treatment responses and the inability to effectively halt disease progression. Extracellular vesicles (EVs) are nanoscale membranous particles actively secreted by cells, which are capable of transporting bioactive molecules such as nucleic acids and proteins to mediate intercellular communication. Owing to the broad cellular origins and excellent biocompatibility of EVs, these particles offer extensive therapeutic potential. This review systematically elaborates on the key aspects of EVs, including the core molecular composition of these particles, as well as the biogenesis pathways and functional regulatory mechanisms involved. We further dissect the functional heterogeneity of EVs derived from cardiomyocytes, cardiac fibroblasts, endothelial cells, and immune cells in HF, highlighting the dual roles of EVs in either promoting or counteracting disease progression via cargo-dependent mechanisms. Additionally, we explore the translational applications of EVs in the diagnosis and treatment of HF, covering EV isolation, characterization, and scalable production strategies. The potential use of EVs as biomarkers, as well as the precision engineering of EVs for targeted clinical therapy, are also critically discussed.
    Keywords:  biomarkers; engineering treatment; extracellular vesicles; functional heterogeneity; heart failure
    DOI:  https://doi.org/10.31083/RCM46117
  6. Cells. 2026 Feb 05. pii: 304. [Epub ahead of print]15(3):
      Exosomes and other extracellular vesicles (EVs) carry microRNAs, proteins, and lipids that reflect cardiovascular pathophysiology and can enable minimally invasive biomarker discovery. However, EV datasets are highly dimensional and heterogeneous, strongly influenced by pre-analytic variables and non-standardized isolation/characterization workflows, limiting reproducibility across studies. Artificial intelligence (AI), including machine learning (ML), deep learning (DL), and network-based approaches, can support EV biomarker development by integrating multi-omics profiles with clinical metadata. These approaches enable feature selection, disease subtyping, and interpretable model development. Among the AI approaches evaluated, ensemble methods (Random Forest, gradient boosting) demonstrate the most consistent performance for EV biomarker classification (AUC 0.80-0.92), while graph neural networks (GNNs) are particularly promising for path integration but require larger validation cohorts. Evolutionary neural networks applied to EV morphological features yield comparable discrimination but face interpretability challenges for clinical use. Current studies report promising discrimination performance for selected EV-derived panels in acute myocardial infarction and heart failure. However, most evidence remains exploratory, based on small cohorts (n < 50) and limited external validation. For clinical implementation, EV biomarkers need direct comparison against established standards (high-sensitivity troponin and natriuretic peptides), supported by locked-in assay plans, and validation in multicenter cohorts using MISEV-aligned protocols and transparent AI reporting practices. Through a comprehensive, integrative, and comparative analysis of AI methodologies for EV biomarker discovery, together with explicit criteria for reproducibility and translational readiness, this review establishes a practical framework to advance exosomal diagnostics from exploratory research toward clinical implementation.
    Keywords:  artificial intelligence; biomarkers; cardiovascular disease; exosomes; extracellular vesicles; multi-omics
    DOI:  https://doi.org/10.3390/cells15030304
  7. Diagnostics (Basel). 2026 Feb 01. pii: 430. [Epub ahead of print]16(3):
      Cardiac amyloidosis is an infiltrative cardiomyopathy caused by extracellular deposition of misfolded proteins, most commonly immunoglobulin light chains (AL) or transthyretin (ATTR), with rarer forms occurring less frequently. AL amyloidosis arises from plasma cell-derived light chains and typically follows an aggressive clinical course, whereas ATTR amyloidosis results from misfolded wild-type or variant transthyretin and progresses more indolently. Extracellular vesicles (EVs) have recently been recognized as mediators of amyloid propagation, inflammation, and myocardial remodeling, particularly at later stages of disease. Despite growing evidence, no comprehensive reviews have focused on this relationship. We conducted a structured narrative review (PubMed and Scopus, 2020-2025) following Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines to synthesize emerging data. EVs act as scaffolds for transthyretin and serum amyloid A aggregation and carry disease-specific protein and RNA cargo detectable in blood and urine. Experimental models also demonstrate EV-mediated transport of serum amyloid A under conditions of cardiac stress, representing a reactive amyloidogenic pathway rather than a common cause of human cardiac amyloidosis. Preclinical studies show regenerative and anti-fibrotic effects of stem-cell-derived EVs, and early clinical trials demonstrate the feasibility of EV-based cardiac therapy. While methodological and translational challenges persist, EVs represent promising diagnostic and therapeutic tools that could transform the precision management of cardiac amyloidosis.
    Keywords:  amyloid cardiomyopathy; biomarkers; cardiac amyloidosis; extracellular vesicles; precision medicine; transthyretin
    DOI:  https://doi.org/10.3390/diagnostics16030430
  8. Brain. 2026 Feb 10. pii: awag049. [Epub ahead of print]
      Small extracellular vesicles (sEVs) efficiently transport pathological RNAs in ischemic stroke, yet whether penumbral hypoxia-induced EVs deliver pathogenic cargo to remote regions, impacting acute ischemic stroke outcomes, remains unclear. Using a focal ischemia mouse model, we isolated brain-derived EVs (BDEVs) from the cortical penumbra and determined their pathological impact on synaptically connected remote regions. In vitro, penumbra BDEVs (PEVs) exacerbated recipient neuronal damage, intensifying apoptosis and dendritic injury during oxygen-glucose deprivation/reoxygenation. In vivo tracing confirmed PEV transport via anatomical projections to remote thalamic neurons, where internalization triggered synaptic loss and apoptosis in distal thalamic nuclei. Mechanistically, PEVs delivered the penumbra-specific circular RNA CircOGDH through trans-synaptic delivery to connected thalamic neurons, directly inducing synaptic and neuronal injury. Critically, cortical CircOGDH knockdown abolished thalamic CircOGDH accumulation and reversed neuronal loss and synaptic impairment, confirming its causal role in secondary damage. Transcriptomics further revealed PEV enrichment in RNAs dysregulating synaptic and axonal pathways. Thus, we open a new view PEVs initiated a thalamus pathogenic pathway where BDEVs deliver CircOGDH and functional RNAs to drive non-infarcted region degeneration. This redefines remote post-stroke injury as an active RNA trafficking process, highlighting therapeutic opportunities for intercepting EV-mediated trans-synaptic pathology.
    Keywords:  brain-derived extracellular vesicles; corticothalamic pathway; ischemic stroke; non-coding RNA; penumbra
    DOI:  https://doi.org/10.1093/brain/awag049
  9. Mol Neurobiol. 2026 Feb 11. 63(1): 431
      Intracerebral hemorrhage (ICH) is a life-threatening cerebrovascular disorder frequently accompanied by blood-brain barrier (BBB) disruption. Endothelial apoptosis is a key contributor to BBB damage, leading to loss of barrier function, exacerbation of brain edema and inflammation, and a cascade of adverse outcomes. Previous studies have shown that extracellular vesicles (EVs) released from M2-polarized microglia are enriched in neuroprotective miRNAs; however, their effects on endothelial cells after ICH and the underlying mechanisms remain unclear. This study aimed to determine the protective effects of M2‑EVs and their enriched miRNAs on vascular endothelial cells after ICH and to elucidate the relevant target genes and signaling pathways. Microglia were polarized to the M2 phenotype by IL‑4 stimulation, and EVs were isolated from M0‑ and M2‑polarized microglia. EVs were characterized by Western blotting, nanoparticle tracking analysis (NTA), and transmission electron microscopy (TEM). The effects of M2‑EVs on endothelial cells were evaluated in both in vitro and in vivo ICH models. In vitro, transendothelial electrical resistance, TUNEL staining, CCK‑8 assays, Western blotting, immunofluorescence, and TEM were used to assess endothelial apoptosis and tight junction integrity. In vivo, BBB disruption and brain edema after ICH were assessed by EB extravasation, MRI, and brain water content, and endothelial apoptosis and tight junction damage were further examined by Western blotting, immunofluorescence, and TEM. Neurological recovery was evaluated using neurological severity scores, rotarod and corner tests, and gait analysis. Candidate miRNAs were screened by sequencing, and their therapeutic effects, target genes, and downstream signaling pathways were validated. In both in vitro and in vivo ICH models, M2‑EVs reduced endothelial apoptosis, preserved tight junctions, and attenuated BBB disruption, thereby alleviating brain edema, limiting hematoma expansion and ameliorating neurological deficits in mice. miRNA sequencing identified miR‑27b‑3p, enriched in M2‑EVs, as a key mediator. miR‑27b‑3p directly targeted MKK4 and reduced phosphorylation of MKK4 and JNK in endothelial cells. This, in turn, increased the Bcl‑2/Bax ratio, helped maintain mitochondrial homeostasis, decreased mitochondrial release of cytochrome c (Cyt c), and lowered the expression of the downstream apoptotic effector Caspase‑3. As a result, endothelial apoptosis was suppressed and tight junction integrity was maintained, which mitigated BBB‑related neurological dysfunction after ICH. This study demonstrates that M2‑EVs, particularly those enriched in miR‑27b‑3p, protect the BBB after ICH by targeting the MKK4/JNK signaling pathway, increasing the Bcl‑2/Bax ratio and stabilizing mitochondrial function. These changes reduce Cyt c release and Caspase‑3 expression, thereby inhibiting endothelial apoptosis, preserving BBB integrity and improving neurological outcomes in mice at 3 days post‑ICH. Together, these findings suggest that miR‑27b‑3p carried by M2‑EVs represents a promising neurovascular protective strategy with considerable translational potential for the treatment of hemorrhagic stroke.
    Keywords:  Apoptosis; Blood–brain barrier; EVs; Endothelial cell; ICH; MicroRNA; Microglia
    DOI:  https://doi.org/10.1007/s12035-026-05718-x
  10. J Nanobiotechnology. 2026 Feb 13.
      Blood-brain barrier (BBB) impermeability remains a major obstacle to the effective treatment of neurological disorders, particularly ischemic stroke. Here, we revealed that plant-derived extracellular vesicle-like nanoparticles (PEVs) offer a promising strategy to overcome this barrier. Using an optimized high-yield extraction protocol, we isolated PEVs from four medicinal plants: Panax ginseng, Panax notoginseng, Gastrodia elata, and Ligusticum chuanxiong. Among these, extracellular vesicles derived from Panax notoginseng (NotoEV, vesicle population) exhibited the strongest neuroprotective effects under hypoxic conditions in vitro and in vivo stroke models. Mechanistically, NotoEV delivered conserved plant microRNAs to recipient neurons, where they suppressed key stress granule nucleators GTPase-activating protein-binding protein 2 (G3bp2), Ubiquitin-associated protein 2 like (Ubap2l), and LSM14A mRNA processing body assembly factor (Lsm14a), activated mammalian target of rapamycin (mTOR) signaling, and promoted mitochondrial stabilization via the B-cell lymphoma 2 (Bcl-2)/ Translocase Of Outer Mitochondrial Membrane 20 (TOM20) axis. This cross-kingdom RNA delivery reprogrammed neuronal stress responses, reduced infarct volume, preserved neuronal morphology, and restored electrophysiological function. Collectively, our findings establish a scalable platform for plant-based nanotherapeutics and highlight the translational potential of NotoEV in treating ischemic stroke.
    Keywords:  Cross-kingdom miRNA; Ischemic stroke; Mitochondrial stabilization; Neuroprotection; Plant-derived extracellular-vesicle-like nanoparticles; Stress granules; mTOR signaling
    DOI:  https://doi.org/10.1186/s12951-026-04103-z